VenatoRx Pharmaceuticals announced that it has received an investment of $8.9M from the Wellcome TrustTranslation Fund for the “Development of novel small molecules for the treatment of antibiotic resistant bacterial infections.”

VenatoRx is developing new antibacterial therapeutic products to address multi-drug resistant gram negative bacteria, including resistant E. coli, K. pneumoniae, and P. aeruginosa, important causative agents for complicated urinary tract infections, complicated intra-abdominal infections and many types of serious pneumonia.